Results 91 to 100 of about 61,873 (295)
Deuteration of Six‐Membered N‐Heteroarenes: Chemistry and Applications
Deuterated six‐membered N‐Heteroarenes (6NHetAr) are finding utility in an increasing repertoire of applications. Our paper comprehensively reviews synthetic approaches that have been reported for the deuteration of 6NHetAr and their fused counterparts while providing an overview of established and emerging applications for these materials.
Liju Raju +4 more
wiley +1 more source
Drug-induced tardive dyskinesia
Tardive dyskinesia (TD) is a type caused by the use of different medications. The pathogenesis of TD is associated with dopamine receptor blockade, gamma-aminobutyric acid depletion, cholinergic deficiency, oxidative stress, impaired synaptic plasticity,
T. M. Ostroumova +3 more
doaj +1 more source
Respiratory dyskinesia--an under-recognized side-effect of neuroleptic medications [PDF]
Respiratory dyskinesia is an under-recognized side effect of neuroleptic administration. There are only few studies that have addressed the prevalence of respiratory dyskinesia in patients with tardive dyskinesia.
Bhimani, Mukesh Mohan
core +1 more source
Wearable biosensors based on molecularly imprinted polymers
Wearable biosensors based on molecularly imprinted polymers (MIPs) provide real‐time, non‐invasive monitoring of key biomarkers. This review highlights the research advances on MIPs‐based biosensors with enhanced selectivity, stability, and adaptability in flexible sensing platforms.
Xiangnan Li +3 more
wiley +1 more source
Physical Function–Tardive Dyskinesia (PATD) on Critical Patients in Intensive Care Unit
Introduction: Critical patients are patients who potentially get reversible dysfunction in one or more life-threatening organs and require care in the Intensive Care Unit (ICU). Methods: The objective of this research is to analyse the physical function-
Heru Suwardianto +3 more
doaj +1 more source
Tardive dyskinesia is a persistent movement disorder induced by chronic neuroleptic exposure. NBI‐98854 is a novel, highly selective, vesicular monoamine transporter 2 inhibitor.
Christopher F. O’Brien +6 more
semanticscholar +1 more source
Abstract Valbenazine improved chorea in individuals with Huntington's disease compared to placebo in a phase 3, placebo‐controlled study (KINECT‐HD). Population pharmacokinetics (PK) and exposure–response (E–R) analyses focused on understanding the PK characteristics of valbenazine and its active metabolite, [+]‐α‐dihydrotetrabenazine ([+]‐α‐HTBZ), and
Hoa Q. Nguyen +5 more
wiley +1 more source
Norio Yasui-Furukori,1 Atsuhiro Kikuchi,1 Hiroshi Katagai,1,2 Sunao Kaneko11Department of Neuropsychiatry, Hirosaki University School of Medicine, 2Department of Neuropsychiatry, Hirosaki-Aiseikai Hospital, Hirosaki, JapanBackground: Tardive dystonia and
Yasui-Furukori N +3 more
doaj
ObjectiveFour types of antipsychotic-induced movement disorders: tardive dyskinesia (TD), parkinsonism, akathisia and tardive dystonia, subtypes of TD (orofacial and limb truncal dyskinesia), subtypes of parkinsonism (rest tremor, rigidity, and ...
P Roberto Bakker +5 more
doaj +1 more source
MRI brain scan study of minor physical anomalies to aid the early diagnosis of autism [PDF]
Poster Sessionspublished_or_final_versionThe 27th International College of Neuropsychopharmacology Congress (CINP 2010), Hong Kong, China, 6-10 June 2010. In International Journal of Neuropsychopharmacology, 2010, v. 13, suppl. S1, p. 182, abstract no. P-
Cheung, C +7 more
core +1 more source

